Octrado introduces its proprietary trading offering: “Your Skill. Our Capital”

Infrastructure, transparent rules and clear legal boundaries positioned as the core of the funded-account model
VICTORIA, Seychelles, Sept. 09, 2026 (GLOBE NEWSWIRE) — Octrado introduces its proprietary trading, a service that gives traders access to firm capital through a structured evaluation process. Under the model “Your Skill. Our Capital”, the platform positions itself between the retail trader and the funded-account system, with the emphasis placed on the operational layer – data environment, rule clarity, evaluation and payouts – rather than on headline account sizes alone.

Provectio accélère le développement de son centre de formation avec un catalogue enrichi

L’ESN Provectio franchit une nouvelle étape dans le développement de son centre de formation. Après l’obtention de la certification Qualiopi en début d’année, l’entreprise accélère son développement en enrichissant son catalogue de formations.  Après avoir initié son activité de centre de formation avec des sessions dédiées à Microsoft 365, Provectio étend désormais son offre à l’intelligence artificielle ainsi qu’à l’administration des systèmes d’information, afin d’accompagner les entreprises dans l’évolution de leurs compétences numériques.

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China

SHENZHEN, CHINA, Sept. 09, 2026 (GLOBE NEWSWIRE) — On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China.

Athernal Bio Secures Innovate UK Grant to Advance Cancer Interception in High-Risk Leukaemia

London, UK, September 9, 2026 – Athernal Bio, a UK biotechnology company pioneering cancer interception, today announced it has been awarded a grant of nearly £700,000 through Innovate UK’s Growth Catalyst – Investor Partnerships programme. The non-dilutive funding will accelerate the development of Athernal’s lead immunotherapy programme, designed to intercept the earliest stages of acute myeloid leukaemia (AML) before cancer becomes established. The award comes alongside continued support from existing investor Delin Ventures.

Athernal Bio Secures Innovate UK Grant to Advance Cancer Interception in High-Risk Leukaemia

London, UK, September 9, 2026 – Athernal Bio, a UK biotechnology company pioneering cancer interception, today announced it has been awarded a grant of nearly £700,000 through Innovate UK’s Growth Catalyst – Investor Partnerships programme. The non-dilutive funding will accelerate the development of Athernal’s lead immunotherapy programme, designed to intercept the earliest stages of acute myeloid leukaemia (AML) before cancer becomes established. The award comes alongside continued support from existing investor Delin Ventures.

Premium Catering (Holdings) Limited Receives NASDAQ Notice Related to Late Filing of Its Interim Report

New York, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) — Premium Catering (Holdings) Limited (NASDAQ: PC, or the “Company”), today announced that today announced that it has received a letter from the Nasdaq Stock Market, dated September 4, 2026 (the “Delinquency Letter”), notifying the Company that it is not in compliance with the requirements for continued listing set forth in NASDAQ Listing Rule 5250(c)(1) because it did not timely file its interim report on Form 6-K containing an interim balance sheet and income statement for its fiscal half year ended December 31, 2025 (the “2026 Interim Report”), it no longer complies with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires that listed companies timely file all required periodic financial reports with the Securities and Exchange Commission. In accordance with Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Delinquency Letter to submit a plan to regain compliance with the Rule (the “Compliance Plan”). If Nasdaq accepts the Compliance Plan, Nasdaq may grant the Company an extension until 180 calendar days from the date of the 2026 Interim Report’s due date, or December 28, 2026, to regain compliance. The Company intends to submit the Compliance Plan within the prescribed 60-day period.

Tradition Announces Partnership With Affin Moneybrokers to Support Malaysian Market Data

SINGAPORE, Sept. 09, 2026 (GLOBE NEWSWIRE) — Tradition today announced a strategic partnership with Affin Moneybrokers Sdn. Bhd., one of Malaysia’s leading interbank money brokers, under which Tradition will provide market data infrastructure, pricing technology and distribution capabilities to support Affin’s continued growth in the Malaysian financial markets.